Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ecucizumab for acute exacerbation of refractory generalized myasthenia gravis (real‑world study)
ChiCTR2600128850Phase 4Not yet recruiting
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of eculizumab in myasthenia gravis (MG), sponsored by The Affiliated Hospital of Xuzhou Medical University. Primary endpoint: Improvement ratio of MG-ADL score at week 12. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
eculizumab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on ChiCTR2600128850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600128850.